Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24724319 | 1.00 | TRPV4 (0.36) | TRPV4CYP3A4CYP2D6TSHRCRHBP | |
| SCHEMBL12197725 | 0.83 | CYP3A4 (0.43) | TRPV4CYP3A4CYP2D6TSHRCRHBP | |
| SCHEMBL24774970 | 0.80 | TRPV4 (0.36) | TRPV4CYP3A4CYP2D6TSHRCRHBP | |
| SCHEMBL20113151 | 0.80 | TRPV4 (0.41) | TRPV4CYP3A4CYP2D6TSHRCRHBP | |
| SCHEMBL24635085 | 0.80 | TRPV4 (0.36) | TRPV4CYP3A4CYP2D6TSHRCRHBP | |
| SCHEMBL24724318 | 0.80 | TRPV4 (0.36) | TRPV4CYP3A4CYP2D6TSHRCRHBP | |
| SCHEMBL28807428 | 0.80 | ESR1 (0.31) | — | |
| SCHEMBL13093308 | 0.78 | TRPV4 (0.35) | TRPV4CYP3A4CYP2D6TSHRCRHBP | |
| Hydrochloric Acid SCHEMBL29220543 | 0.78 | TRPV4 (0.35) | TRPV4CYP3A4CYP2D6TSHRCRHBP | |
| Hydrochloric Acid SCHEMBL29220586 | 0.78 | TRPV4 (0.35) | TRPV4CYP3A4CYP2D6TSHRCRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287070-A1 | FUSED HETEROCYCLIC DERIVATIVES | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| US-20240279227-A1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN BIOTECH, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-117881661-A | Condensed heterocyclic derivative | 杨森科学爱尔兰无限公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4347036-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347590-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2024-04-10 | — | — | EP | disclosed |
| CN-117715909-A | Condensed heterocyclic derivative | 杨森科学爱尔兰无限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2022253255-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253259-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287070-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | TRPV4 4510/4885CYP3A4 4/4885CYP2D6 41/4885 |
| US-20240279227-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | TRPV4 4510/4885CYP3A4 4/4885CYP2D6 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.